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AXL, a receptor tyrosine kinase, is known to promote malignant phenotypes in various 
types of cancer. AXL overexpression is commonly observed in glioblastoma and correlates with a 
worse prognosis. Detectable in most biological fluids, the extracellular domain of AXL, sAXL, is 
the product of enzymatic cleavage by ADAM10/17. Here we used ELISA, BCA and BCG assays 
to characterize blood serum from 23 newly diagnosed GBM patients which was collected roughly 
24 hours before and after surgery as well as every three months post-surgery, corresponding to 
follow-up treatment visits. Immunoblotting was used to determine relative AXL expression in 13 
patient tumor tissue samples. Additionally, T-1 weighted MRI scans were used to interpolate pre-
operative tumor volume in all participating patients. Here we report that sAXL was elevated in the 
84 GBM samples compared to the 40 control samples (p = 0.013). Normalizing sAXL values 
against corresponding serum albumin concentrations further defined the distinction between the 
two groups (p < 0.0001). While in the 19 paired, pre- and post- operative samples, sAXL did not 
respond significantly to surgical intervention, normalizing the values against albumin showed a 
significant elevation in response to surgery (p = 0.013). In patients whose pre-operative samples 
presented with sAXL elevated compared to the healthy control average (30.16 ng/mL), there was a 
strong positive correlation between sAXL and AXL found in the corresponding tumor tissue. 
Though sAXL shed from brain tumors is detectable in the serum of GBM patients, in this small 
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Based on the 2016 World Health Organization’s Classification System of Tumors 
of the Central Nervous System, Glioblastoma Multiforme (GBM) is categorized as a 
grade IV diffuse glioma due to its origin in glial progenitor cells and diffuse growth 
pattern 1. Glioblastoma is the most aggressive form of malignant primary brain cancer 
and affects about 3 individuals out of 100,000 each year in the United States alone 2. 
Patients symptoms present quickly and can include headaches, abnormal physical 
weakness and neurological abnormalities such as memory loss, confusion, blurred vision 
or speech and loss of consciousness 3.  Identification and subsequent diagnosis of the 
disease is first determined by imaging techniques like CT or MRI scans followed by a 
craniotomy to obtain a sample for molecular diagnostic testing 3. Standard treatment 
involves maximal tumor resection followed by radiation and adjuvant chemotherapy 4. 
Untreated, median survival time is only about 3 months2. Even with standard treatment, 
median survival for GBM patients is about 15 months 5. GBM patient survival is 
dependent on many factors including, but not limited to, age at diagnosis, sex, tumor 
location and treatment type 6. However variable that may be, overall survival of GBM 
patients 5 years after diagnosis is less than 5% 7. Because of the difficulties associated 
with treating this disease, it is of the utmost importance to develop techniques that would 
aid in the detection of GBM and monitor treatment progress.  
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Cancer cells, in part, are distinct from normal cells in the composition of surface 
proteins that reside on the cell membrane 8. Tyrosine kinases represent a minority of the 
protein-coding portion of our genome but have played a dominate role in cancer research 
since the discovery of the first proto-oncogene, src. Mutations that lead to constitutively 
active forms of these signaling molecules can lead to cellular transformation. In fact, 
deregulated signaling mechanisms are a defining characteristic of all neoplastic growths9. 
This is represented in a central dogma of cancer research that malignant growths arise 
from the accumulation of mutations in both an oncogene and a tumor suppressor gene. 
These mutated genes or the product of their expression are frequent points of interest in 
the study and treatment of cancer.  
One way these tyrosine kinases can be separated into categories is based on the 
location in which they function, the plasma membrane or the cytoplasm10. Receptor 
tyrosine kinases (RTK) are found embedded in the plasma membrane and largely 
function as the primary point of contact for environmental stimuli. These proteins 
translate the signal from the extracellular environment through a process of enzymatic 
reactions to the intracellular environment. Tyrosine kinases found in the cytoplasm 
function as a cascade of mediators that typically transfer the signal from the membrane to 
a vast range of targets within the cell, resulting in a response to the original stimuli. These 
responses can range from translocation of transcription factors into the nucleus, in turn 
modulating gene expression11, to the activation of cell proliferation or apoptotic 
mechanisms12.  
The process of RTK activation is initiated by the binding of a ligand to a pair of 
its receptor proteins, often simultaneously13, resulting in activation of the dimer complex. 
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On the cytoplasmic side of this complex, the act of dimerization facilitates 
autophosphorylation and then transphosphorylation of tyrosine residues on its subunits 
that attract docking proteins containing SH2 domains. Cytoplasmic kinases interact with 
this docking complex and pass the signal further downstream to ultimately affect some 
kind of cellular response14. While point mutations causing constitutively active kinases 
are one common cause of aberrant molecular signaling, simple overexpression of normal 
RTK’s is another15.  
One such case is that of receptor tyrosine kinase AXL (Ufo, Ark), a member of 
the TAM kinase family along with Tyro3 (Sky) and Mer, and serve as key players in 
numerous normal and malignant cellular functions. In 1988, the gene that codes for AXL 
was first characterized as a novel proto-oncogene in human myeloid leukemia cells16. 
Canonical activation of the AXL receptor dimer complex involves the binding of its 
natural ligand, Growth-arrest specific factor 6 (Gas6), as well as interacting with the 
phospholipid, phosphatidylserine (PtdSer)17–19. However, studies have suggested that in 
the cases in which AXL is overexpressed, heterotypic activation20 and even ligand-
independent receptor activation can occur21. When expressed normally and often in 
concert with the other members of the TAM family, activation of AXL promotes various 
normal cellular behaviors seen across different cell types. These include apoptotic cell 
clearance22,23, dampening of cytokine induced inflammation 11,24, migration and survival 
of certain types of neurons25–27 and Vascular Smooth Muscle Cells (VSMC) cells28–30, 




Whereas standard expression and activation of AXL leads to normal cellular 
functions, overexpression has been shown to cause aberrant signaling that results in 
malignant phenotypes (Figure 1) 35,36. Described below, these phenotypes include 
increased survival, proliferation, migration, invasion, angiogenesis, immune suppression 
and decreased sensitivity to chemotherapeutic intervention. AXL signaling has been 
shown to stimulate cellular proliferation and protect from apoptosis through the 
MEK/ERK35 and PI3K/Akt/NF-κB37,38 pathways. Invasion and migration are controlled 
through pathways like Rac/p38 MAPK and ERK/MMP9 respectively. Angiogenesis has 
been connected to AXL through in vivo studies demonstrating cross-talk between AXL 
and VEGFR-2 activated Src family kinases (SFK), leading to downstream activation of 
the PI3K/Akt pathway39. Immune suppression, primarily in the form of dampening the 
responses of the immune system caused by cytokine release and TLR activation, is 
facilitated by AXL negative regulation of the TLR and cytokine-associated receptors (eg. 
IFNAR)24,11,37. Decreased drug sensitivity is a result of AXL-related mechanisms, one of 
which involves upregulation of signaling proteins and transcription factors such as BCL-
2 and Twist40. Furthermore, the upregulation of various AXL-related pathways result in 
epithelial to mesenchymal transition (EMT) in various cell types41–43.           
 Studies have been undertaken to understand the implications of aberrant AXL 
signaling for patients with different cancers. In short and as summarized by Rankin and 
Giaccia44, AXL plays a significant role in the phenotypic expression of different cancer 
cells and is therefore a valuable therapeutic target. High AXL expression has been 
correlated with worse survival rates in at least 14 types of cancer, including GBM45–59.  
Additionally, AXL expression has been shown to confer drug resistance to cells in at 
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least five types of cancer40,59–64. Furthermore, AXL has been demonstrated to be an 
important conduit to the molecular rewiring necessary for EMT and/or the maintenance 
of this state in GBM65, breast cancer41–43, ovarian cancer66, NSCLC67 and pancreatic 
cancer68. Taken together, these studies have demonstrated the significant role that 
aberrant AXL signaling may play in numerous cancers and has bolstered efforts to target 
AXL when treating these diseases.  
  Due to the similar effects of AXL overexpression and activation across a variety 
of cancer subtypes, increased focus has been placed on using AXL-targeted drug therapy. 
Various AXL inhibitors are at different stages of development with promising pre-
clinical results69,70 suggesting that in specific cancers, these drugs can significantly 
supplement the effectiveness of current treatments.  Use of AXL-targeting small-
molecule inhibitors such as, Bemcentinib (BGB324; previously R428), and others are 
currently at different phases of clinical trials in patients with GBM71 (NCT03965494), 
pancreatic cancer72 (NCT03649321), NSCLC73,74 (NCT02922777, NCT02424617) and 
AML/MDS75 (NCT02488408). However, despite the advanced stage of some of these 
clinical trials, the long term efficacy of AXL targeting has not been reported. Although 
these clinical efforts oriented towards treatment strategies are valuable, identification of 
the disease at its earliest stages would drastically change the outcomes for the majority of 
patients. 
Specifically in GBM, AXL and Gas6 have been reported to be moderate to highly 
expressed at both the mRNA and protein level in in the majority of cases. Similarly, in 
patient tissue samples with high AXL levels, determined by IHC, AXL and Gas6 
expression were correlated with shorter time to disease progression and was associated 
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with a poor survival rate. Furthermore, AXL protein expression was only found to be 
present in glioma tumor tissue and its vasculature, but absent in non-neoplastic tissues45. 
Another study reported that AXL was elevated in GBM and was correlated with a worse 
prognosis and showed that AXL overexpression directly correlated with drug resistance 
and contributed to tumorigenesis59. There are numerous studies reporting significant 
expression of AXL in various regions of the brain, however, a comprehensive study 
performed in 2015 resulting in the Human Protein Atlas, indicates that of all the organs 
where AXL protein expression is found, it is least abundant in the brain76. These studies 
highlight the role AXL plays in GBM, from its origin through the treatment and outcome 
of the patient.  
Cellular regulation of AXL can be found at all levels of expression, from 
transcriptional controls to post-translational deactivation through enzymatic cleavage. 
Environmental stimuli trigger the cell to release transcription factors, several of which 
have been demonstrated to act upon the axl gene. Several transcription factors like 
MZF177, STAT111, HIF1α78 and AP179 have been shown to induce axl transcription. 
However, methylation of CpG islands adjacent to the transcription factor binding sites 
have been demonstrated to play an antagonistic role in the generation of axl mRNA80. 
Once transcribed, axl mRNA does not always result in translation. In fact, despite 
relatively equivalent expression of axl mRNA in different cell types, protein level AXL 
expression is significantly different between cell types76,81. Post-transcriptional regulation 
can take the form of ribosomal blockades by miRNAs such as miR-199a/b82 and miR-
34a82,83, preventing the translation of the AXL mRNA. Even after translation, the AXL 
protein can also be subject to ubiquitination and subsequent degradation84. Another post-
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translational means of protein regulation is modification by ADAM proteins that have 
been shown to regulate AXL activity by enzymatically cleaving the extracellular 
domain21,85. The regulatory process for protein creation and function is a complex and 
finely tuned system that nevertheless offers various points to target for detection or 
treatment of AXL-influenced diseases. 
This soluble form of AXL, denoted sAXL, is nearly ubiquitous in the body since 
it is a product of membrane AXL, whose expression is nearly ubiquitous on some level. 
This is also partially due to the small size of sAXL (43 kDa) making it capable of 
permeating certain blood vessels86. Presumably due to a lack in uniformity of testing, 
there is a range of reported sAXL concentrations in blood serum from healthy control 
populations. Regardless, sAXL can be found in the majority of the relevant biological 
fluids such as blood serum87 or plasma88,89, cerebrospinal fluid90, urine91 and peritoneal 
effusions92. Evidence supporting the existence of a soluble AXL extracellular domain 
(sAXL) generated due to proteolytic cleavage, as opposed to alternative transcript 
splicing, was first published in 1995. Based on their evidence and previous studies 
examining soluble forms of EGFR and other RTKs, the authors theorized that sAXL 
acted as an regulator of full-length RTK function by binding the receptor’s natural ligand 
and down-regulating its signaling function93. Further studies confirmed that cleavage of 
the extracellular domain of AXL can serve as a dual-function regulator of AXL signaling 
activity. By releasing the ligand binding domain, sAXL prevents the initiation of 
dimerization94 and it can bind Gas6 in the ECM, further preventing initiation of the 
signaling cascade78.  
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Evidence has been put forward to suggest the important role this regulatory 
mechanism may play in malignant diseases. As reported by Miller et al., 94 certain kinase 
inhibitors can cause reduced ADAM-mediated RTK cleavage, including AXL, and was 
inversely correlated with progression-free survival in a cohort of melanoma patients. In 
this study, the use of mitogen-activated-protein-kinase (MAPK) inhibitors showed 
significantly decreased proteolytic cleavage of AXL, MET and HER4. In melanoma 
xenograft models, the inhibition of TIMP1, the natural inhibitor of ADAM proteins, 
restored sheddase activity. When combined with MAPK inhibition, there was a 
synergistic effect, resulting in a reduction of tumor growth and metastasis94.  
Due to the demonstrable link between AXL overexpression and various diseases, 
numerous studies have examined localized AXL tissue expression and the release of 
sAXL as potential means of detecting diseases or monitoring treatment. Elevated sAXL 
levels have been seen in chronic liver diseases such as liver fibrosis and cirrhosis95,96 and 
hepatocellular carcinoma 95–98. Another significant study demonstrated a strong 
association between sAXL and tumor progression, as well as patient survival, in renal 
cell carcinoma 99. Similar studies have connected sAXL, or its natural ligand Gas6, to a 
myriad of other diseases or physiological conditions such as melanoma100, ovarian 
carcinoma92, systemic lupus erythematosus89,101,102, large abdominal aortic aneurysms 88, 
severe preeclampsia 103,104, tumor burden in Neurofibromatosis Type 1 105, myocardial 
infarction87 and heart failure106,107. A possible correlation exists between sAXL and GBM 
however, based on available records, direct evidence of this has not been reported.  This 
project will be the first to investigate the possible distinctive presence of circulating 




Figure 1: AXL Signaling Pathway Overview 
(Top Left) Illustrations representing the immunosuppressive effects of AXL activation in several 
types of immune cells. (Bottom Right) Simplified illustration showing the general phenotypic 
expressions that result from AXL activation and downstream signaling through several significant 
pathways. Taken from “Giving AXL the Axe: Targeting AXL in Human Malignancy” Gay CM, 








Figure 2: Regulating RTK Signaling Through Sheddase Activity 
(A) Illustration representing ADAM-dependant sAXL shedding as a means ofdisrupting the 
AXL/Gas6 complex, therefore dampening the effects of AXL signaling. (B) Inhibition of ADAM 
proteins bypasses this regulation of AXL, leads to the accumulation of ADMA-related RTK 
proteins and serves to amplify signaling cascades.  
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AIMS AND GOALS 
 
 
Glioblastoma lethality is in part due to the aberrant molecular signaling pathways 
facilitated by RTKs. The RTK AXL promotes malignant phenotypes in GBM and other 
cancers through myriad intracellular signaling pathways. Due to a unique type of 
regulatory mechanism, facilitated by ADAM10 and ADAM17, the extracellular portion 
of AXL is found circulating in the blood. This is true in the case of cancer patients and 
healthy populations alike. The aim of this study is to compare the relative abundance of 
sAXL in the blood of GBM patients and healthy volunteers then to use this as a means of 
establishing sAXL as a novel biomarker for GBM. 
I hypothesized that circulating sAXL in blood serum collected from GBM 
patients would be elevated compared to a volunteer control population. I further 
hypothesized that sAXL levels in samples collected after surgery would be lower than 
paired samples collected prior to surgical intervention. It was also predicted that a change 
in circulating sAXL levels would be reflected in samples collected while patients were 
undergoing chemo- and radiation therapy. Lastly, I hypothesized that circulating sAXL 
levels would reflect AXL expression in corresponding tumor tissue as well as tumor 




METHODS AND MATERIALS 
 
 
Obtaining Blood Serum Samples 
Blood serum samples from 29 Northern Michigan University undergraduate 
students enrolled in CLS 100 (phlebotomy) were a generous gift provided for this 
research during the Winter 2019 semester. Blood samples were collected during the 
course while practicing basic phlebotomy techniques. Samples were collected in Gold-
top serum separator tubes that were labeled with a de-identified number that 
corresponded to each student along with their age and sex.  Tubes were centrifuged at 
1000 rpm for 5-10 minutes then the supernatant was collected and aliquoted into 0.65 mL 
Eppendorf tubes. Tubes were labeled and stored at -80° C.  To expand this control 
population, approval from Northern Michigan University’s Institutional Review Board 
(IRB) was obtained in order to recruit 13 faculty members to donate blood for this study. 
A student, experienced in phlebotomy, obtained the samples and used similar labeling as 
described to maintain volunteer confidentiality. These blood serum samples were treated 
as described previously.  
Approval from the Aurora Health Care IRB was obtained for the collection of 
blood serum, tissue specimens, and supplemental research information. Blood serum 
samples were collected from GBM patients undergoing surgery at Aurora St. Luke’s 
Hospital in Milwaukee Wisconsin. Of the 27 patients enrolled in the study, 23 of them 
had confirmed GBM tumors by the Hospital’s pathology lab. Blood serum samples from 
these patients were collected before surgery, after surgery, and up to 7 time points 
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corresponding with follow-up visits approximately every three months. These samples 
will hereafter be referred to as pre-operative, post-operative, and BL1-7, respectively. A 
sum of 84 GBM samples from 23 GBM patients was acquired for this study. Half of 
these were from the pre- and post-operative time points, the other half from the bi-
monthly “treatment timeline”. Of the 42 pre- and post-operative samples, 38 were 
collected from the same patient before and after surgery. All samples were labeled with a 
de-identified number and the corresponding time point.  
Dilution Scheme for Serum Samples 
 The blood samples were prepared as 1:200 dilutions, resulting in two 
500µL aliquots by a two-step serial dilution in both Low-Cross Buffer™ (Candor 
Biosystems) or Phosphate Buffered Saline (Dulbeco). These samples were stored at  
-80°C for subsequent testing. Additionally, three 50µL aliquots of blood serum were 
stored to mitigate freeze-thaw cycles of the original blood samples. These smaller 
aliquots would be used for BCG assays to determine the total serum Albumin 
concentrations while the 1:200 dilutions in either LCB or PBS would be used for either 












Figure 3: Serum Dilution Scheme.  
The general plan used to mitigate freeze-thaw cycles and inter-assay variation caused by dilution. 
From the same serum sample, multiple aliquots were prepared in LCB (1:200), PBS (1:200) or 
undiluted for the three assays to be implemented (ELISA, BCA and BCG).   
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Preparation of Human AXL ELISA Kit 
Human AXL DuoSet ELISA kits (R&D Biosystems) were purchased along with 
the corresponding Ancillary Reagent Kits (DY008). The AXL capture and detection 
antibodies were allowed to sit at room temperature for 15 minutes prior to diluting in 
PBS, aliquoting in single-use portions and storage at -80° C. Following the 
manufacturer’s instructions, 1mL of PBS was added to the vial containing capture 
antibody in order reconstitute it, resulting in a 360µg/mL stock solution which was 
sufficient antibody for at least 15 assays. Similarly, the detection antibody vial was 
reconstituted with 1mL of reagent diluent (1% BSA in PBS, pH 7.2-7.4, 0.2uM filtered), 
resulting in a 9µg/mL solution that was sufficient to perform at least 15 assays. The 
recombinant AXL protein standards came in three separate vials containing 80ng of 
lyophilized protein each. After warming to room temperature, one vial was reconstituted 
in 500µL of room temperature LCB to a final stock concentration of 160ng/mL. Each  
solution was aliquoted into single-use quantities and stored at -80° C. The streptavidin-
HRP solution came in a light-resistant vial and was stored undiluted at 4° C As a part of 
my optimization of the ELISA protocol, the working concentration standards were later 
prepared in one large serial dilution to the final concentrations of 4000, 2000, 1000, 500, 
250, 125, 62.5 and 0 pg/mL in LCB at a final volume of 6mL each. These solutions were 
then split into 14 aliquots and frozen at -80° C. This would ensure that all samples are 




Enzyme-linked Immunosorbent Assay 
The night before each assay, an aliquot of AXL capture antibody was thawed on 
ice and was diluted 1:180 in PBS, to a final volume of 10mL at a concentration of 2.0 
µg/mL. Using an 8-well multichannel pipette, 100µL of this solution added to each well 
of a 96-well plate provided with the ancillary reagent kits. The plate was sealed with a 
transparent adhesive strip, centrifuged briefly at 3000rpm to ensure even coating of all 
wells. The plate was then allowed to sit at room temperature overnight on an even 
surface.  
The following morning, the plate was inverted to expel the solution into a waste 
container and blotted against a clean paper towel. The plate was then washed three times 
with 300µL of wash buffer (0.05% tween® 20 in PBS, pH 7.2-7.4), inverting, and blotting 
the plate against a clean paper towel each time to ensure complete removal of fluid. The 
plate was then blocked by adding 300µL of reagent diluent to each well and allowed to 
sit at room temperature for 2 hours. During this time, diluted samples in LCB and diluted 
AXL standards were thawed on ice, vortexed, and centrifuged briefly to ensure even 
distribution. Next, 160µL of each sample was transferred to a designated 96-well 
“transfer plate”, mirroring the intended locations on the ELISA plate. Using a “transfer 
plate” rather than pipetting individual samples into 94 wells served to minimize any 
variation of sample volume added between wells and exposure time to capture antibody. 
After the blocking step, the plate was washed three times exactly as before. Using the 8-
well multichannel pipette, 100µL was transferred from each column of the “transfer 
plate” to the ELISA plate, changing tips for each set of samples. The plate was 
centrifuged briefly to ensure even distribution of the samples and allowed to incubate at 
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room temperature for 2 hours. The wash step was then repeated as before. This was 
followed by the addition of 100µL of AXL detection antibody (50.0 ng/mL) to each well 
using a multichannel pipette. The plate was centrifuged briefly and allowed to incubate 
for 2 hours. Following another wash step, 50 µL of Streptavidin-HRP was warmed to 
room temperature and diluted 200-fold in reagent diluent. Then 100µL of this solution 
was added to each well and allowed to incubate for 20 minutes. The plate was washed 
and then coated with 100 µL of a 1:1 mixture of color reagent A (hydrogen peroxide) and 
color reagent B (tetramethylbenzidine). After a 20-minute incubation, the reaction was 
halted by the addition of 50µL of stop solution (2N sulfuric acid). The plate was 
immediately transferred to a spectrophotometer to measure the optical density of each 
well at two wavelengths, 450 and 540nm. The 540nm measurement was used as a 
wavelength correction by subtracting these values from the 450nm values. After adjusting 
for background values by normalizing against the blanks, a four-parameter logarithmic 
curve-fit was generated in GraphPad Prism based on the standard curve and use to 
interpolate the concentrations of the samples. Standards on each plate were tested in 
duplicate and each sample was tested in triplicate and repeated at least once, either on a 
separate day or on a duplicate plate. 
Optimizing the AXL ELISA for Ideal Interassay Variation 
In the earliest stages of this project, samples were tested only once in triplicate but 
due to early results suggesting promise for this assay it was decided that repeating 
measures would offset limited sample availability as well as demonstrate another critical 
assay performance characteristic, inter-assay variation. However, repeating the assay on 
separate dates revealed an objectively high level of inter-assay variation, calling into 
19 
 
question the results of our previously collected data. To counteract this phenomenon, 
several strategies were implemented, the first of which included preparing the samples in 
the appropriate buffers and dilutions prior to testing and storing them at -80°C as 
duplicate aliquots (see figure 3).  
A simple experiment was first implemented to ensure that storing the diluted 
samples at -80° C would not affect protein interpolated concentrations. For 13 randomly 
selected serum samples, 1:200 dilutions in LCB and PBS and three smaller, undiluted, 
aliquots were prepared. These samples were stored together at -80° C until the day of 
testing. On the day of testing, the previously undiluted samples were prepared identically 
to its counterpart samples and tested for sAXL and total protein using the standard 
ELISA and BCA protocols, respectively. Samples diluted on the day of testing and those 
stored frozen collectively showed no significant difference in protein concentration in 
either the ELISA (figure 4) or BCA assay (figure 5).  
All samples were then prepared as seen in Figure 3, however, after the first 
ELISA was performed it was evident that the inter-assay variation was still present 
(figure 6). From the protein stability experiment, it became apparent that the most 
significant missing variable was the standards to which the diluted samples were 
compared. Afterward, a batch preparation of AXL recombinant protein standard was 
serially diluted but, on a scale, large enough to perform each of the remaining ELISAs 
twice. The diluted standards were aliquoted and stored at -80° C together and thawed on 
the day of testing. Together, preparing the diluted samples and standards resulted in a 
drastically reduced inter-assay variation and was confirmed by a paired t-test (figure 7).  
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Bicinchoninic Acid (BCA) Assay to Determine Total Serum Protein 
Samples diluted 1:200 in PBS were thawed on ice, mixed via vortex and 
centrifuged briefly. BCA standards (Thermofisher) previously were prepared at 
concentrations of 2000, 1500, 1000, 750, 500, 250, 125, and 0 µg/mL in molecular grade 
water. After samples and BCA standards were warmed to room temperature, 50µL of the 
standards were added to a transfer plate in duplicate. Next, 100µL of the diluted samples 
were added to the plate in triplicate, mirroring the sample layout used in the ELISA 
experiments. Using an 8-well multi-channel pipette, 25 of each sample was transferred to 
a clean 96 well plate, one column at a time. Next, 200µL of a mixture of BCA reagents A 
and B (1:50) was added to each well. After a 30-minute incubation at room temperature, 
the plate was measured for optical density at 562nm. Standards used were tested in 
duplicate and each of the samples was tested in triplicate. Concentrations were 
interpolated from a standard curve, adjusted by the dilution factor, and were converted 
from µg/mL to g/dL by dividing by a factor of 10,000. 
Bromocresol Green (BCG) Assay to Determine Total blood albumin 
 Frozen aliquots of blood serum were thawed on ice, diluted 1:2 in ultra-pure 
water, and transferred to a 96-well plate. Frozen BSA standards at concentrations of 5, 4, 
3, 2, 1.5, 1, 0.5, and 0 g/dL were thawed on ice and transferred to the 96-well plate. Next, 
200µL of BCG reagent was added to each well and incubated for five minutes at room 
temperature. The plate was then read for optical density at 620nm. Using GraphPad 
Prism, a four-parameter logarithmic curve-fit was generated and used to interpolate the 
sample concentrations. Standards used were tested in duplicate and each sample was 
tested in triplicate. The BCG assay functions as a specific quantitative measurement of 
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albumin due to the formation of a chromophore upon the interaction of BCG and 
albumin.  
Tissue Sonication 
Frozen tumor tissue samples that were acquired were obtained by the ARI 
Biorepository and Specimen Resource Center (BSRC) who stored them at -80° C until 
ready for transfer to the ARI lab. Frozen tissues were briefly thawed on ice prior to being  
transferred to a sonication tube, also on ice, with clean forceps. The original tubes were 
rinsed with ice-cold RIPA buffer containing protease inhibitors and transferred to the 
sonication tube. Tubes were weighed before and after to determine tissue mass. Ice-cold 
RIPA buffer was added to a final volume of 500 µL in each tube. Samples were then 
sonicated twice at 10% amplitude for 10 seconds and three times at 15% amplitude or 
until the homogenate became transparent. Samples were immediately placed back on ice 
in between sonication bursts and great care was taken to keep the sonication probe in the 
middle of the mixture to avoid frothing. These homogenates were subsequently 
centrifuged at 14,000 rpm at 4° C for 10 minutes to pellet any insoluble material. The 
remaining supernatant was removed with a pipette, and 50 µL aliquots were stored at -
80° C.  
Western Blotting  
Protein concentration for each of the 15 tumor lysates was determined by BCA 
assay (Thermofisher) using minimal lysate (10µL/ well). Using the interpolated 
concentration was then used to calculate the volume needed to load 40ug of total protein 
per well. Ice-cold RIPA buffer was used to normalize the volume and a consistent 
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amount of 4x LSB (BioRad) containing 10% β-mercaptoethanol was added to each tube. 
Samples were denatured at 95° C for 5 minutes and immediately chilled on ice. 
Denatured samples were loaded in a 4-12% Criterion™ Bis-Tris gel (BioRad) and ran at 
80v for approximately 1.5 hours. The proteins were transferred to a PVDF membrane 
using the iBlot® 2 (Thermofisher) semi-dry transfer system. The membrane was blocked 
in 5% molecular grade NFDM blocking buffer (BioRad) for 1 hour. It was then washed 
three times for 5 minutes in 1x TBS (BioRad). The membrane was covered in 5% 
blocking buffer containing AXL antibody diluted 1:200 and incubated overnight at 4° C 
on a shaker. The next morning the membrane was washed three times in TBST (0.1% 
tween) for 10 minutes. Secondary, mouse anti-goat, antibody diluted 1:2000 in blocking 
buffer was added to the membrane and was allowed to incubate for one hour (RT), with 
shaking. The membrane was washed as before and developed by covering it drop-wise 
with a 1:1 mixture of clarity peroxide reagent and clarity luminol reagent (BioRad) and 
incubating for five minutes. The blot was then immediately transferred to a LiCore 
imaging system and read for 2 minutes on the chemiluminescent channel and 5 minutes 
on the 700nm channel. The membrane was then stripped of antibodies by coating the 
membrane in OneMinute® Stripping Buffer (GM Biosciences), blocked for one hour in 
5% NFDM and washed three times in TBST (0.1% Tween20). The membrane was coated 
in an rabbit anti-actin primary antibody (1:2000 in 5% NFDM) incubated overnight at 4° 
C on a shaker. The following morning the membrane was washed three times for 10 
minutes in TBST (0.1% Tween20). The membrane was then coated in anti-rabbit 
secondary antibody (1:2000 in 5% NFDM) for 1 hour at room temperature. This was 
followed by three washes for 10 minutes in TBST (0.1% Tween20). The membrane was 
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then developed by covering it drop-wise with a 1:1 mixture of clarity peroxide reagent 
and clarity luminol reagent (BioRad) and incubating for five minutes at room 
temperature. The blot was then immediately transferred to a LiCore imaging system and 
read for 2 minutes on the chemiluminescent channel and 5 minutes on the 700nm 
channel.  
Pre-Operative MRI analysis  
MRI scans taken for each of the 27 enrolled patients were completely de-
identified and made available in BrightMatter Plan (Synaptive Medical, Toronto, CAN), 
the software used by Aurora St. Luke’s to plan surgeries. Training in the software was 
conducted by an experienced neuroradiologist, how to distinguish tumor tissue from other 
enhancing regions of the brain. BrightMatter Plan was used to analyze all of the pre-
operative T-1 weighted scans of the patients and build a 3D model of the tumor.  The 
software automatically calculates the tumor volume. Each analysis was reviewed and 
modified when necessary to ensure their accuracy. 
Data Analysis 
 Determination of statistically significant variation between two groups was 
performed using a two-tailed, unpaired student’s t-test unless noted otherwise. For 
datasets with three or more groups were analyzed using repeated measures, mixed-model, 
one-way ANOVA with Dunnett’s post hoc. Graphical representation of datasets were 
performed in GraphPad with error bars representing either 95% confidence intervals or 




Characterizing sAXL in GBM and Healthy Control Populations 
 It was hypothesized that sAXL would be significantly elevated in patients with 
GBM as a result of elevated membrane AXL release from tumor tissue as a result of 
enzymatic cleavage. Investigating this in the broader sense meant performing ELISAs on 
GBM and control samples using the optimized methodology previously mentioned. Since 
the sample size was somewhat limited compared to other studies investigating protein 
biomarkers, a somewhat larger data set was generated by testing each sample in triplicate 
and on two separate occasions. Including other variables, such as serum albumin or total 
serum protein, would also allow for a more powerful statistical analysis of these two 
populations. After testing 124 samples as previously described, sAXL was found to be 
significantly elevated in the GBM population (35.77 ± 1.25, n=84) compared to the 
healthy population (30.16 ± 1.88, n=40; p = 0.013) (Figure 8). Upon further comparison 
of each population, normalizing the sAXL values against serum albumin (Figure 11) and 
total protein (Figure 12), the distinction became even more apparent in both cases  
(P <  0.0001). This increased distinction was due to the finding that GBM patients had 
significantly lower serum albumin (P <  0.0001) (Figure 9) and total serum protein (P <  
0.0001) (Figure 10) compared to the control population. Additionally, sorting the samples 
by gender in each category (healthy or GBM), no significant difference was seen in any 

































Figure 4: Protein Stability Test: ELISA 
sAXL concentrations (ng/mL) for paired samples previously diluted and stored at -80°C 
(33.8±3.24, n=13) versus samples prepared the day of testing (34.06±3.52, n=13). Statistical 
significance of variation was calculated using a two-tailed, paired student’s t-test. Concentrations 
and error bars presented as mean ± SEM.  






























Figure 5: Protein Stability Test: BCA assay 
Total protein concentrations (g/dL) for paired samples previously diluted and stored at -80°C 
(6.17±0.26, n=12) versus samples prepared the day of testing (6.41±0.20, n=12). Statistical 
significance of variation was calculated using a two-tailed, paired student’s t-test. Concentrations 
and error bars presented as mean ± SEM.  















































































Figure 6: ELISA Inter-assay Variation: Individual Protein Standards 
Sample ID vs. sAXL concentrations for samples prepared and stored identically then tested on 
two separate dates. AXL recombinant protein standards used were prepared on the day of testing. 
Statistical significance of variation was calculated using a two-tailed, paired student’s t-test. Error 
bars presented as mean ± SEM.  














































































Figure 7: ELISA Inter-assay Variation: Batch-Prepared Protein Standards 
Sample ID vs. sAXL concentrations for samples prepared and stored identically then tested on 
two separate dates. AXL recombinant protein standards used were prepared as a batch and 
aliquoted for multiple tests. Statistical significance of variation was calculated using a two-tailed, 
paired student’s t-test. Error bars presented as mean ± SEM.   





Table 1: sAXL Summary Data 
 
Sample Type N sAXL (ng/mL) Albumin (g/dL) sAXL/Albumin Ratio
Healthy (n=40) 30.16±1.88 5.89±0.16 5.38±0.44
F (n=27) 28.67±1.92 5.86±0.17 5.09±0.46
M (n=13) 33.26±4.2 5.97±0.35 6±0.98
GBM (n=84) 36.31±1.45 4.24±0.07 8.68±0.34
F (n=26) 30.16±1.88 4.39±0.11 7.94±0.51
M (n=58) 34.57±2.46 4.17±0.08 9.01±0.44
Pre-Op (n=20) 30.74±1.96 4.35±0.12 7.28±0.56
F (n=8) 29.22±3.35 4.25±0.17 6.66±0.85
M (n=12) 31.75±2.48 3.92±0.14 7.69±0.75
Post-Op (n=22) 32.32±2.26 3.76±0.1 8.87±0.73
F (n=9) 29.61±2.48 3.92±0.14 7.74±0.73
M (n=13) 34.2±3.4 3.65±0.13 9.66±1.1
BL1 (n=9) 39.42±4.73 4.83±0.14 8.31±1.16
F (n=3) 48.52±9.6 4.97±0.14 9.89±2.28
M (n=6) 34.87±4.77 4.77±0.21 7.52±1.35
BL2 (n=6) 49.11±6.98 4.32±0.29 11.52±1.57
F (n=1) 66.3±0 5.35±0 12.39±0
M (n=5) 45.68±7.44 4.11±0.24 11.35±1.91
BL3 (n=7) 38.77±3.86 4.34±0.19 9.12±1.09
F (n=1) 29.29±0 4.55±0 6.43±0
M (n=6) 40.35±4.17 4.3±0.22 9.56±1.18
BL4 (n=6) 40.32±1.75 4.18±0.3 10.03±1.11
F (n=2) 36.56±2.8 4.25±0.47 8.78±1.63
M (n=4) 42.21±1.67 4.14±0.43 10.66±1.5
BL5 (n=6) 35.81±3.4 4.38±0.23 8.35±1
F (n=1) 34.92±0 4.74±0 7.37±0
M (n=5) 35.99±4.16 4.3±0.26 8.55±1.2
BL6 (n=3) 45.42±3.57 4.48±0.22 10.18±0.86
F (n=1) 49.37±0 4.89±0 10.11±0
M (n=2) 43.45±5.16 4.27±0.11 10.22±1.48
BL7 (n=5) 32.95±4.56 4.32±0.39 7.95±1.6
F (n=0) 0±0 0±0 0±0
M (n=5) 32.95±4.56 4.32±0.39 7.95±1.6
Descriptive statistics table outlining concentrations of sAXL (ng/mL), Albumin (g/dL) and the corresponding 
ratio between them. Groups first separated based on cohort (GBM vs. Healthy), further separated based on 






























Figure 8: sAXL in GBM and Healthy Blood Serum 
Serum sAXL concentrations are elevated in GBM patient samples (35.77 ± 1.25, n=84) compared 
to healthy volunteer samples (30.16 ± 1.88, n=40; p = 0.013). Grouped sAXL concentrations are 
listed as mean ± SEM. Violin plots above represent the group median (solid line) and quartiles 
(dashed lines). Statistical significance of variation was calculated using a two-tailed, unpaired 
student’s t-test.  






















Figure 9: Serum Albumin in GBM and Healthy Blood Serum 
Serum albumin concentration are elevated in the healthy volunteer samples (5.89 ± 0.16, n=40) 
compared to the GBM patient samples (4.235 ± 0.07, n=84) (P <  0.0001). Collective Albumin 
concentrations are listed as mean ± SEM. Violin plots above represent the group median (solid 
line) and quartiles (dashed lines). Statistical significance was calculated using a two-tailed, 
unpaired student’s t-test.  
























Figure 10: Total Protein in GBM and Healthy Blood Serum 
Total protein concentration are elevated in the healthy volunteer samples (7.43 ± 0.15, n=40) 
compared to the GBM patient samples (5.98 ± 0.093, n=74) (P < 0.0001). Collective total protein 
concentrations are listed as mean ± SEM. Violin plots above represent the group median (solid 
line) and quartiles (dashed lines). Statistical significance was calculated using a two-tailed, 
unpaired student’s t-test.  






















Figure 11: sAXL/Albumin Ratio in GBM and Healthy Blood Serum 
Values from each sample’s measured sAXL concentration normalized against the average of the 
corresponding serum albumin concentration for each sample. Ratios for GBM patient samples 
(8.68 ± 0.34, n=84) are elevated compared to the healthy volunteer samples (5.38 ± 0.44, n=40) 
(P < 0.0001). Collective ratios are listed as mean ± SEM. Violin plots above represent the group 
median (solid line) and quartiles (dashed lines). Statistical significance was calculated using a 
two-tailed, unpaired student’s t-test.  


























Figure 12: sAXL/Total Protein Ratio in GBM and Healthy Blood Serum 
Values from each sample’s measured sAXL concentration normalized against the average of the 
corresponding total protein concentration for each sample. Ratios for GBM patient samples (6.20 
± 0.23, n=74) are elevated compared to the healthy volunteer samples (4.14 ± 0.23, n=40) (P < 
0.0001). Collective ratios listed as mean ± SEM. Violin plots above represent the group median 
(solid line) and quartiles (dashed lines). Statistical significance was calculated using a two-tailed, 
unpaired student’s t-test.  



































Figure 13: Serum sAXL Concentration in Males and Females Separated by GBM 
Status  
Serum sAXL concentrations for healthy (solid fill) and GBM (diagonal pattern) samples 
separated by male (blue) and female (red). Concentrations were not significantly different 
between genders in either the healthy or GBM cohorts. Error bar represent 95% confidence 




Using sAXL as a Predictive Biomarker for GBM Presence 
In order to test the hypothesis that sAXL was a predictive biomarker for the 
presence of GBM, pre-operative serum samples (as opposed to all the GBM serum 
samples) were compared to the healthy controls. First, comparing sAXL in the pre-
operative and post-operative samples to the healthy control would serve to distinguish 
sAXL as a marker for the presence of GBM at the point of surgery. However, considering 
only sAXL, neither the pre-operative or post-operative samples compared to the healthy 
control showed a significant difference (Figure 14). Making this same comparison with 
serum albumin alone showed that healthy samples had elevated concentrations of serum 
albumin as compared to both groups (P <  0.0001) (Figure 15). For this reason, 
normalizing sAXL against serum albumin was able to distinguish sAXL in both pre-
operative (P =  0.013) and post-operative populations (P <  0.0001) from the control 
population (Figure 16). This suggests that sAXL concentration is not sufficient to predict 
GBM presence but comparisons to other serum proteins may be sufficient in making the 
































Figure 14: sAXL Concentrations: Control, Pre-operative and Post-operative 
samples 
Serum sAXL concentrations are not elevated in pre-operative (30.84 ± 2.07, n=19) or post-
operative samples (32.04 ± 2.44, n=19) compared to the healthy control samples  
(30.16 ± 1.88, n=40). Similarly, sAXL concentrations did not significantly change in response to 
surgery. Concentrations for each group are listed as mean ± SEM. Violin plots above represent 
the group median (solid line) and quartiles (dashed lines). Statistical significance between healthy 
and GBM samples were calculated using an unpaired t-test. Statistical significance between 
paired GBM samples was calculated with a paired t-test.  





























Figure 15: Serum Albumin Concentration: Control, Pre-operative and Post-
operative samples 
Serum albumin concentrations are significantly elevated in the healthy control population  
(5.89 ± 0.16, n=40) compared to both pre-operative (4.34 ± 0.12, n=19) (P < 0.0001) and post-
operative samples (3.70 ± 0.10 n=19) (P < 0.0001). Additionally, serum albumin concentrations 
are elevated in the pre-operative samples compared to post-operative samples (p = 0.0002). 
Concentrations for each group are listed as mean ± SEM. Violin plots above represent the group 
median (solid line) and quartiles (dashed lines). Statistical significance between healthy and 
GBM samples were calculated using an unpaired t-test. Statistical significance between paired 
GBM samples was calculated with a paired t-test.  








































Figure 16: sAXL Normalized by Albumin: Control, Pre-operative and Post-
operative samples 
Serum sAXL concentrations normalized by albumin concentrations from the healthy control 
(5.384 ± 0.44, n=40), pre-operative (7.32 ± 0.59, n=19) and post-operative samples  
(8.84 ± 0.77, n=19). Values calculated as a ratio between individual sAXL concentrations and the 
mean albumin concentration for each sample, collectively listed as mean ± SEM. Violin plots 
above represent the group median (solid line) and quartiles (dashed lines). Statistical significance 
between healthy and GBM samples were calculated using an unpaired t-test. Statistical 
significance between paired GBM samples was calculated with a paired t-test. 











Serum sAXL in Response to Surgical Intervention  
Since the first step in the treatment of GBM is the maximal amount of tumor 
resection, it would follow that removal of sAXL releasing tumor tissue should result in an 
overall reduction in serum sAXL following surgery. It was shown that pre-operative 
samples tested only for sAXL showed no significant difference compared to the healthy 
controls (Figure 14), but when normalizing by serum albumin a distinction was made 
(Figure 16). Despite this, it became apparent that there was no significant difference in 
sAXL as a result of surgical intervention, in roughly half the patients sAXL levels rose 
and in the other half, they fell with no noticeable trend (Figure 17). However, performing 
this same comparison with sAXL concentrations normalized to serum albumin showed a 
distinct upward trend as determined by a two-tailed, paired t-test between the 19 matched 
samples (P =   0.019) (Figure 18). Moreover, an interesting correlation appeared from 
this dataset when interpolated tumor volumes were included in the analysis. To represent 
the change in sAXL between each time point, pre-operative sAXL values were subtracted 
from their corresponding post-operative values (n=19). These values were then plotted 
against pre-operative tumor volume, fit with linear regression and evaluated for a 
correlation using the Pearson method (Figure 19). The result was a significant correlation 
(P =  0.013) between tumor volume and net change in circulating sAXL. The trend 
shows that after surgery, patients with larger tumors tended to result in a net increase in 
sAXL after surgical intervention and smaller tumor volumes tended to result in a net 
































Figure 17: Change in Serum sAXL: Pre-Post Surgery  
No significant change is seen in response to surgery as determined by a two-tailed, paired t-test. 
Individually matched serum sAXL concentrations from patient samples before (n=19) and after 





























Figure 18: Change in Normalized Serum sAXL: Pre-Post Surgery 
Serum sAXL/albumin ratios are significantly elevated after surgery (P = 0.019) as determined by 
a two-tailed, paired t-test. Each dot represents the average of 6 replicates and each line connects 
the paired samples. Individually matched serum sAXL concentrations from patient samples 



























Figure 19: Pre-opertaive Tumor Volume vs.  Change in sAXL 
Elevation in serum sAXL levels observed after surgery directly correlates with tumor volume. 
Solid blue line represents best-fit line determined by standard linear regression. Dotted line 
represents baseline, no change, in sAXL. Correlation (r) and significance (P) values calculated 




Serum sAXL in Response to Treatment  
Looking past the point of surgery (ie. Post-operative time point) to the treatment 
time points was attempted to test the hypothesis that sAXL was capable of tracking 
disease progression and treatment response. It can be seen that the number of samples 
acquired by each patient during this phase dropped precipitously. Despite this, it is also 
apparent that sAXL tended to be at its highest during the period following surgery once 
standard treatment regimens had begun (Table 1, figure 20). However, upon 
characterizing the treatment timeline samples and comparing against the post-operative 
samples did not showed any significant effect as determined by a mixed-model one-way 
ANOVA (Figure 20). Similar to previous comparisons, sAXL concentrations were 
normalized against serum albumin but did not show any significant effect in treatment 
timeline samples from the healthy controls and the surgical samples as determined by a 
mixed-model one-way ANOVA (Figure 21). Together these data suggest, but cannot 
confirm, that the significant elevation of sAXL in the GBM population as a whole 
compared to the control population (Figure 8), is primarily in response to either treatment 









































Figure 20 : sAXL at Each Treatment Timepoint and Post-operative Samples 
Serum sAXL concentrations from GBM patient samples, separated by treatment time point 
showed no significant effect compared to the post-operative samples. Violin plots above represent 
the group median (solid line) and quartiles (dashed lines). Statistical significance of variation for 
paired samples was calculated using a mixed-model one-way ANOVA.  













































Figure 21: sAXL Normalized by Albumin at Each Timepoint and Postoperative 
Samples 
Serum sAXL concentrations normalized by serum albumin from GBM patient samples, separated 
by treatment time point showed no significant effect compared to the post-operative samples. 
Values calculated as a ratio between individual sAXL concentrations and the mean albumin 
concentration for each sample. Violin plots above represent the group median (solid line) and 
quartiles (dashed lines).Statistical significance of variation for paired samples was calculated 
using a mixed-model one-way ANOVA.  




Associations between sAXL, AXL and Tumor Volume 
In all, 16 tissue samples were made available for western blotting. Of these, 14 
were GBM, one was an astrocytoma, and one was a tumefactive demyelinating process 
(MS). One of the GBM tissue samples was so small, a high enough concentration of 
protein could not be extracted for western blotting. With the remaining 15 samples, the 
protein concentration of the homogenates was estimated using BCA assays. Next, 40 µg 
of protein was loaded in a 4-12% Criteron™ Bis-Tris gel (BioRad), and separation of 
protein was achieved via gel electrophoresis and transferred to a PVDF membrane. This 
membrane was then blocked in 5% NFDM blocking buffer and blotted for AXL (1:2000) 
and β-Actin (1:2000). The membranes were developed using BioRad chemiluminescent 
substrate solutions, imaged and analyzed using Image Studio software (Li-COR 
Biosciences) (Figure 24). The optical density (OD) of the bands was interpreted and by 
dividing the AXL O.D by the actin OD, a value representing relative AXL expression 
was obtained.  
Pre-operative tumor volumes for all 23 GBM patients enrolled in the study were 
determined using de-identified T1-weighted MRI scans using BrightMatter Plan software 
(Figure 25). This was done by scrolling up and down through the axial plane of the scans, 
highlighting enhancing regions with the brush tool that logically corresponded to tumor 
tissue (i.e. excluding ventricles and apparent blood vessels). All analyses were reviewed 
and when necessary edited, by a board-certified neuroradiologist. All scan files were 
labeled with the de-identified number and time point that corresponded with its matched 
serum sample. Tumor volumes interpolated from these scan files were transcribed by 
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hand, cross-checked, and manually transferred into a composite sAXL excel spreadsheet 
used to perform all statistical analyses. 
Determining correlations between membrane AXL (mAXL) was performed using 
GraphPad software by inputting matched patient data, such as pre-operative sAXL and 
membrane AXL expression values, then performing a correlation analysis using the 
Pearson method. As a whole, comparing mAXL expression to pre-operative sAXL 
concentrations yielded no clear correlation (r= 0.15) (Table 2). However, when patient 
samples are broken into groups based on sAXL concentration, a new pattern emerged. 
Similar to methods performed in Hutterer et al.45, those patients with pre-operative sAXL 
concentrations ≥30 ng/mL (the average healthy sAXL concentration) were placed in the 
“sAXL High” group and the remainder in the “sAXL Low” group. Repeating these 
comparisons with each group then revealed a number of interesting correlations, the most 
significant of which being pre-operative sAXL in the “high” group is directly correlated 
with membrane AXL expression (r= 0.85) (Table 3, Figure 26).  
A somewhat weaker correlation was made between pre-operative sAXL/albumin 
ratio and mAXL (r= 0.65) (Table 2). Moreover, in the “Low” group, there were several, 
moderate to strong, negative correlations made between mAXL and the following 
characteristics: pre-operative sAXL, pre-operative sAXL/albumin ratio, post-operative 
sAXL, post-operative sAXL/albumin ratio and pre-operative tumor volume (Table 2). 
These negative correlations indicate that larger mAXL expression results in smaller 
values in the corresponding variable. This is most interesting in the case of pre-operative 
tumor volume as it suggests that in the largest tumors lies the greatest retention of AXL 
on the plasma membrane, perhaps as a result of reduced proteolytic cleavage.  
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Evaluating associations with pre-operative tumor volume was performed as 
before but using volume as the dependent variable. In the collective GBM sample group 
(n=13), the strongest correlation was a moderate one with post-operative sAXL/albumin 
ratio group (Table 3). Once separated into “High” and “Low” groups, tumor volume 
showed no strong correlations. Of the moderate correlations, tumor volume was 
negatively correlated with pre-operative sAXL and normalized sAXL and positively 
correlated with post-operative sAXL and normalized sAXL (Table 3) but only in the 
“high” group. In the “low” group, volume was moderate-positively correlated with pre-
operative, post-operative sAXL values and as previously mentioned, mAXL expression 
(Table 3). Based on the limited dataset, this suggests that the strongest associations lie 
between tumor volume and mAXL, as well as between tumor volume and post-operative 





Figure 22: Membrane sAXL Expression in GBM Tumor Lysates 
Western blots for 15 tissue homogenates, 13 of which are GBM. Membrane AXL expression 
found at ~140kDa (Top). Housekeeping gene, β-Actin expression for corresponding tissue 
samples found at ~40kDa (Bottom). Optical densities of these bands were calculated using Image 





Figure 23: T1 Weighted MRI Scan of GBM Tumor 
Example of tumor volume analysis in BrightMatter Plan software. Enhancing regions showing 
high contrast material uptake were highlighted using the brush tool in the transverse plane 
(bottom left panel) at various increments of distance. Once layers of tumor were highlighted top 
to bottom, tumor volume was interpolated, and a corresponding value would appear in the top 








  Table 2: Associations with membrane AXL    
   All  sAXL-High  sAXL-Low   
    n† r‡ P*   n
† r‡ P*   n
† r‡ P*   
  pre-op sAXL 11 -0.40 0.23  6 0.85 0.03  5 -0.68 0.20   
  pre-op sAXL Ratio 11 -0.27 0.43  6 0.65 0.16  5 -0.56 0.33   
  post-op sAXL 13 -0.49 0.09  7 -0.07 0.88  6 -0.68 0.14   
  Post-op sAXL Ratio 13 -0.42 0.15  7 -0.06 0.90  6 -0.60 0.21   
  Pre-op Tumor Volume 13 -0.33 0.28   7 -0.32 0.48   6 -0.65 0.16   
  
Pearson correlations between membrane AXL as determined by western blotting and other 
patient sample characteristics separated into three groups, all samples with available tissue 
samples, patients with high sAXL (≥30ng/mL) and patients with low sAXL (<30ng/mL). 
† Number of comparisons made. ‡Pearson r value: ±0.3-0.7 is considered a moderate 








  Table 3: Associations with pre-operative tumor volume   
   All  sAXL-High  sAXL-Low   
    n
† r‡ P*   n
† r‡ P*   n
† r‡ P*   
  pre-op sAXL 11 0.15 0.65  6 -0.58 0.23  5 0.49 0.40   
  pre-op sAXL Ratio 11 0.09 0.80  6 -0.31 0.55  5 0.17 0.78   
  post-op sAXL 13 0.32 0.29  7 0.32 0.48  6 0.48 0.34   
  Post-op sAXL Ratio 13 0.50 0.08  7 0.55 0.20  6 0.48 0.34   
  Membrane AXL 13 -0.33 0.28   7 -0.32 0.48   6 -0.65 0.16   
  
Pearson correlations between pre-operative tumor volume and other patient sample 
characteristics separated into three groups, all samples with available tissue samples, patients 
with high sAXL (≥30ng/mL) and patients with low sAXL (<30ng/mL).  
† Number of comparisons made. ‡Pearson r values: ±0.3-0.7 is considered a moderate 

























Figure 24: Pre-operative sAXL is Associated with Membrane AXL 
The 11 patients with both tissue and pre-operative serum samples available were separated into 
two groups, sAXL high (≥ 30 ng/mL, blue) and low (< 30 ng/mL, red) based on pre-operative 
sAXL concentrations. The pre-op sAXL concentration for both of these groups were plotted 
against relative AXL expression determined by western blotting. These values were fitted using 









The receptor tyrosine kinase AXL has been well characterized with regard to its 
implications in various types of cancer, including GBM. However, until now, the soluble 
form of this protein (sAXL) resulting from the proteolytic cleavage by ADAM proteins 
had yet to be explored as a potential biomarker for GBM. Due to the evidence that AXL 
is frequently overexpressed in GBM and that the protein is subject to this unique form of 
post-translational regulation resulting in its release into the circulatory system, it seemed 
possible that this could serve as a means of detecting GBM in a minimally-invasive 
manner.  
While this study was able to generate some supporting evidence, we did not find 
that sAXL can be used to predict the presence of GBM near disease onset. Granted, there 
is a lack of uniformity in the reported values associated with circulating sAXL, in other 
studies in other cancer types examining sAXL as a predictive biomarker. However, those 
studies found a larger difference between the control and study populations. For example, 
sAXL is highly elevated in a number of liver diseases. As reported by Dengler et al.9 in a 
large multicenter study, sAXL was elevated in hepatocellular carcinoma (78.69 ng/mL, 
n= 347) compared to healthy controls (40.15 ng/mL, n=75)97. Our results did not have 
this pronounced difference between healthy and disease but showed some promise for 
using sAXL as a biomarker for GBM, particularly when combined with multiple 
variables.      
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The systematic dilution scheme (see figure 3), where samples were stored diluted 
in order to mitigate freeze-thaw cycles on the limited number of serum samples, showed 
no significant effect on interpreted sAXL concentrations (see figure 4). This approach 
was inspired by the Dengler et al.108 optimization study where they evaluated the stability 
of sAXL when exposed to multiple freeze-thaw cycles. In the same study, they 
demonstrated the necessity of performing a 1:200 dilution of serum in the proprietary 
buffer LowCross™ buffer in order to effectively reduce the masking effect of protein-
rich solutions like blood serum. However, due to high inter-assay variation, it was 
necessary to prepare the AXL protein standards as a batch such that they very closely 
mirror each other in assays performed on different days. This effectively increased the 
assay’s precision as demonstrated by the dramatically reduced inter-assay variation (see 
figures 6 and 7). Further optimization of the assay’s performance characteristics would 
entail acquiring internal controls in the form of purified human AXL protein to assess the 
reliability of the standards being used. Also, to address any concerns regarding accuracy, 
having a set of samples tested at a separate facility using the same protocol would be a 
means of bolstering the confidence of the results.  
Here it was demonstrated that compared to a volunteer population, sAXL is 
elevated in blood serum collected from GBM patients (see figure 8). While sAXL 
concentration was able to distinguish the GBM and control populations in general, the 
bulk of that difference came from the treatment time points, long after the disease had 
become apparent. Incorporating a second characteristic, serum albumin, helped further 
distinguish GBM from healthy controls in nearly all cases. When normalized against 
serum albumin, the pre-operative values were significantly elevated compared to the 
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control group but lower than that of the paired post-operative samples (see figure 16). 
However, the use of albumin, which can change due to something as simple as being 
properly hydrated, is not reliable without confirmation of these findings on a much larger 
scale.  
In order to bolster the predictive capacity of this sort of assay I would suggest 
incorporating other proteins that are more relevant to tumor pathophysiology and are 
similarly subject to sheddase activities. For example, CD147109, TNF110, or HER111 
proteins all play significant roles in cancer cells and are also subject to post–translational 
regulation in an ADAM-dependent manner. In this combinatorial approach as seen in 
Miller et al.94, building a biomarker panel of tumor-relevant proteins could serve to 
increase the predictive efficacy not achieved with sAXL alone or the sAXL/albumin 
ratio. Implementing the protocol in an automated fashion or using another methodology 
such as LC-MS could prove to be a more high-throughput approach, especially if it could 
analyze multiple targets in a similar timeframe.  
Initially, the lack of a distinct trend from pre- to post-operative samples suggests 
that surgical intervention did not significantly impact sAXL levels in paired samples (see 
figure 17). However, there was a modest elevation in sAXL/albumin ratio in these same 
paired samples, suggesting that there was an impact but not significant enough to notice 
by assessing sAXL alone (see figure 18). In general, the blood-brain barrier (BBB) is 
known to be highly restrictive with respect to which macromolecules are able to pass. 
This is partially due to the tight junctions that create a tight seal between the specialized 
ependymal cells that make up the blood-brain barrier112. This is why only lipid soluble112 
and very small molecules (i.e. <400 Da)113 are able to readily pass the BBB without 
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active transport. While the BBB often has increased permeability in glioma for a number 
of reasons114, there does not seem to have been any direct evidence that suggests sAXL is 
restricted from or capable of crossing the BBB. In this study however, sAXL/albumin 
ratios were elevated, instead of decreased, after surgery and the data that showed tumor 
volume correlated with the net change in sAXL after surgery. One explanation for this 
would be that the blood-brain barrier is hampering the release of sAXL in general but not 
completely and only the largest tumors have produced such an excess of sAXL that it has 
become “backed up” and is then released as a result of surgery. One way to test this 
hypothesis would be to collect blood that is aspirated from the surgical site where the 
tumor is located then compare it to blood serum collected contemporaneously from a 
more peripheral blood vessel like the median cubital vein. 
 Theoretically, if sAXL were being released from the tumors in high enough 
quantities to make up a noticeable portion of the total serum sAXL concentration, the 
post-operative concentrations should have decreased relative to pre-operative values. 
However, this is built upon the premise that circulating sAXL is cleared or filtered out 
fast enough to notice a decrease in a timeframe of 24 hours. To date, there do not appear 
to be any publications supporting or refuting this idea directly. A small number of urine 
samples were collected from GBM patients and were tested for sAXL alongside the 
serum samples. Interestingly, sAXL was highly elevated in one of the four samples (data 
not shown), but did not seem related to either the pre-operative or post-operative samples 
and seemed likely related to kidney issues as has been reported before91. One direction I 
would venture in order to explore this idea would be to track the release of sAXL in 
urine, which is found at similar concentrations as those reported for blood serum91, 
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throughout the course of a day in order to assess a normal rate of sAXL release from the 
body.  
Considering that sAXL concentrations were highest during the treatment timeline, 
the elevation could simply be due to upregulated AXL induced by chemotherapeutic 
drugs as demonstrated in the past40. On the other hand, AXL has also been shown to be 
upregulated in drug-resistant forms of numerous cancer subtypes40,67,94,115 and this could 
be another example of that. This study, however, was not designed to evaluate the 
prognostic potential of sAXL and therefore, the curious elevation seen during the 
treatment timeline is a phenomenon left mostly unexplored. A retrospective study of 
outcomes from the patients enrolled could be implemented to assess these effects. 
Regardless, the results of this study suggest that on its own, sAXL would not serve as an 
ideal predictor of GBM prior to the emergence of symptoms.  
One of the most significant limitations in this study was the sample size and 
collection consistency. Understandably, obtaining tissue specimens was not always 
feasible because there is a prioritization hierarchy to which biopsied samples are made 
available. First, the pathology department obtained whatever size specimen was needed 
for diagnostic testing. Second, tissue samples were used to generate primary cell lines 
and this study received whatever was left. Similarly, obtaining blood serum was not 
always possible. In nearly every enrolled patient, some samples were missed due to 
complications in the collection procedure, patients opting out of treatment, etc. 
Additionally, it now appears that sonication on the tumor tissue samples likely resulted in 
the degradation of proteins. Instead, a gentler, more precise method of protein extraction 
should have been implemented. Using either an electric homogenizer or a simple 
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dissociative agent, followed by differential centrifugation should have been used to 
isolate the membrane fractions and would have served our purposes much better and 
produced higher quality western-blots. This would have allowed us to assess AXL 
expression in tumor tissue in a manner comparable to the experimental design seen in 
Hutterer et al.45. 
These shortfalls can be compensated for in a number of ways. Instead of obtaining 
biopsied specimens and performing western blots, a better approach would be obtaining 
sections of formalin-fixed paraffin-embedded (FFPE) tissue and performing 
immunohistochemistry (IHC). This offers several major advantages to obtaining frozen 
tissue, primarily in that it is collected whenever possible and is typically not in short 
supply. Also, fixed tissues can be tested for molecular characteristics using IHC years 
after its collection greatly extending the “shelf-life” of precious samples. Since a 
complete collection of blood serum from all designated indicated time points were 
difficult to obtain for a number of reasons, a viable option would be to supplement these 
samples patient blood serum that is commercially available. Furthermore, the collection 
of non-GBM blood samples including patients with lower grade brain tumors, non-GBM 
tumors that are associated with sAXL like HCC98 would make us better equipped to 
elucidate sAXL’s potential as a GBM biomarker.  
Three of the four hypotheses were rejected:  Circulating sAXL in patient blood 
serum was not significantly decreased following surgical intervention, it was not 
decreased in response to chemotherapy and radiation therapy, and pre-operative sAXL 
did not significantly correlate with tumor volume. Despite this, it is important to consider 
that this was performed on a small scale and with populations that weren’t matched 
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ideally based on age, sex or other demographic characteristics. Due largely to time 
constraints, multifaceted analysis of the MRI scans was not feasible and could have 
answered several of the questions left unanswered here. In the future, the MRI scans will 
be re-examined for further characteristics such as extent of necrosis, cell density of the 
tumors, and infiltrating cells that would not have been readily detected using the T1-
weighted scans. Also, evaluating the relative expression and activity of the sheddase 
ADAM 10/17 in the tumor tissue is a major component of sAXL release that could 
explain the lack of correlation between tumor volume, membrane AXL expression, and 






In this study, we have demonstrated that there is potential for sAXL as a non-
invasive biomarker for GBM but could not confirm it outright. Blood serum 
concentrations of sAXL were found to be elevated in the group of GBM samples 
collected prior to diagnosis and throughout treatment. Utilizing serum albumin 
concentrations as a second characteristic to normalize sAXL against served to distinguish 
pre-operative GBM blood serum from the healthy controls, albeit only modestly. Given 
the highest sAXL levels seen were during treatment instead of prior to diagnosis, sAXL 
alone would not likely function well as a predictive marker. Perhaps most promisingly, in 
a subset of patients, grouped based on the abundance of sAXL relative to the control 
population’s average, pre-operative sAXL levels showed a significant correlation with 
AXL found in corresponding tumor tissue. This would suggest that sAXL is in fact being 
released from tumor tissue and is subsequently detectable in the blood. While the natural 
fluctuations of sAXL may mask this effect, designing a panel of similar proteins could 
prove effective in predicting GBM where sAXL alone could not. Based on the evidence 
presented here, we believe that repeating this study in a larger and modified fashion is 
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